Background: Small fiber neuropathy arises from injury of small C and Aδ fibers and leads to pruritus as well as positive (pain, burning, tingling or stinging sensation) and negative neurological (numbness) symptoms.
Objectives: To give an overview on small fiber neuropathy as a cause for chronic pruritus, the diagnostic approach to this condition, and therapeutic options.
Materials And Methods: A literature search using the terms "small fiber neuropathy", "pruritus", "itch", and "pain" was performed.
Results: Small fiber neuropathy is often associated with systemic diseases. However, it may occur without an underlying cause (idiopathic small fiber neuropathy). To identify small fiber neuropathy as the causal agent of pruritus, a detailed clinical history is essential. By measuring the intraepidermal nerve fiber density from skin biopsies at the sural nerve supplied region (lateral lower leg), the neurological impairment can be quantified. Often, dysfunction of a nerve fiber occurs after morphological changes ensue. Quantitative sensory testing allows the study of impaired function of these small fibers. Therapeutically, it is important to treat the underlying cause of the neuropathy. A symptomatic approach should be taken into account, when the cause cannot be treated. Topical capsaicin, as well as anticonvulsants and/or antidepressants, have been used with good results.
Conclusion: Due to chronification processes, pruritus may persist even after treatment of the underlying cause. Therefore, early identification of small fiber neuropathy and immediate treatment of the cause is crucial for the success of the treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00105-016-3817-z | DOI Listing |
ACS Nano
January 2025
School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210094, P. R. China.
Neural-electronic interfaces through delivering electroceuticals to lesions and modulating pathological endogenous electrical environments offer exciting opportunities to treat drug-refractory neurological disorders. Such an interface should ideally be compatible with the neural tissue and aggressive biofluid environment. Unfortunately, no interface specifically designed for the biofluid environments is available so far; instead, simply stacking an encapsulation layer on silicon-based substrates makes them susceptible to biofluid leakage, device malfunction, and foreign-body reactions.
View Article and Find Full Text PDFNeurobiol Pain
December 2024
Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Painful diabetic neuropathy (PDN) is a challenging complication of diabetes with patients experiencing a painful and burning sensation in their extremities. Existing treatments provide limited relief without addressing the underlying mechanisms of the disease. PDN involves the gradual degeneration of nerve fibers in the skin.
View Article and Find Full Text PDFChin Med
January 2025
Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Zhejiang Chinese Medical University, Hangzhou, China.
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is prevalent among patients receiving paclitaxel chemotherapy, which results in sensory abnormality as well as neuropathic pain. Conventional medications lack effectiveness on PIPN. Clinical trials identified beneficial effects of acupuncture on PIPN among patients receiving chemotherapy.
View Article and Find Full Text PDFJ Neuroophthalmol
November 2024
Ophthalmology Department (AC-C, MF-R, SA-A, RA, BS-D), Seu Maternitat, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain; Faculty of Medicine and Health Sciences (AC-C, SA-A, BS-D), Universitat de Barcelona, Barcelona, Spain; Fundació Per La Recerca Biomèdica-IDIBAPS (MF-R, SA-A, BS-D), Barcelona, Spain; and Ophthalmology Department (MS-G), Consorci Mar Parc de Salut de Barcelona, Barcelona, Spain.
Background: Autosomal Dominant Optic Atrophy (ADOA) is a hereditary optic neuropathy characterized by retinal ganglion cell degeneration and optic nerve fiber loss. This study examined the correlation between clinical and structural parameters in patients with ADOA using optical coherence tomography (OCT) and explored potential clinical biomarkers.
Methods: A cross-sectional, case-control observational study included 27 patients with ADOA and 27 age- and sex-matched healthy controls.
Int J Mol Sci
December 2024
Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes in both Type 1 (T1D) and Type 2 (T2D). While there are no specific medications to prevent or treat DPN, certain strategies can help halt its progression. In T1D, maintaining tight glycemic control through insulin therapy can effectively prevent or delay the onset of DPN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!